Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Troponin Assays Evaluated for Acute MI

By LabMedica International staff writers
Posted on 05 Jun 2018
Print article
Image: The PATHFAST compact immunoanalyzer used for measuring cardiac troponin (Photo courtesy of Mitsubishi Chemical Europe).
Image: The PATHFAST compact immunoanalyzer used for measuring cardiac troponin (Photo courtesy of Mitsubishi Chemical Europe).
In hospital laboratories and in point-of-care testing, cardiac troponin measurements are achieved by various assays, including “contemporary,” “sensitive” and “highly-sensitive” assays.

Due to the absence of standardization, troponin results cannot be transferred from one assay to another, and individual cut-offs must be strictly used in the context of the troponin assay for which they were determined.

Scientists from several intuitions collaborated with Cochin Hospital (Paris, France) and compared the use of nine different cardiac troponin (cTn) assays (two cTnT and seven cTnI) for the diagnosis of non-ST elevation acute myocardial infarction (NSTEMI) in a single multi-center population. The study was conducted in 13 French hospitals: nine centers were involved in patient inclusion and sample collection, with four additional centers involved in the measurement of troponin only and was performed between April 2014 and November 2015. The study included 158 patients (mean age 60 ±17 years), including 23 patients (14%) with NSTEMI.

The teams found that the analytical comparison highlighted a large heterogeneity of cTn assays, as reflected by percentages of patients with detectable cTn, correlation coefficients, Passing-Bablok comparisons and concordance coefficients. Correlations within cTnI assays were good and correlation within cTnT assays was excellent. Diagnostic performances demonstrated that each cTn assay has specific threshold values. Furthermore, some assays HS-cTnI and T, cTnI-Pathfast and cTnI-Centaur indicated high sensitivity and negative predictive value using the limit of detection (LoD) diagnostic strategy.

The authors concluded that all nine cTn assays indicated overall good diagnostic performances for the diagnosis of NSTEMI in emergency departments when the recommended algorithm based on the variation of cTn value between two measurements at admission and three hours later was used. The study was published in the July 2018 issue of the journal Practical Laboratory Medicine.

Related Links:
Cochin Hospital

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.